In this episode Roger Frechette, Co-Founder & Principal at New England PharmAssociates joins host David Thomann for episode #13 of Slice of Life Sciences Real Estate podcast.

In this episode, Chris Bahl, Chief Scientific Officer & Co-Founder of AI Proteins joins host David Thomann for episode #12 of Slice of Life Sciences Real Estate podcast.

In this episode, Jake Lombardo, Co-Founder & CEO at Anodyne Nanotech joins host David Thomann for episode #11 of Slice of Life Sciences Real Estate podcast.

In this episode, Arnav Chhabra, Co-Founder at Satellite Bio joins host David Thomann for episode #10 of Slice of Life Sciences Real Estate podcast.

In this episode, Mimi Yen, CEO & Co-Founder at PhagePro joins host David Thomann for episode #9 of Slice of Life Sciences Real Estate podcast.

In this episode, Bernardo Cervantes, Co-founder at Concerto Biosciences joins host David Thomann for episode #8 of Slice of Life Sciences podcast.

Joining host David Thomann for episode #6 is Kori Rahaim, Vice President, Head of People 4:59 Initiative at 5AM Ventures.

Joining host David Thomann for episode #6 is Stephanie Sousa, Senior Vice President of Operations at a Stealth Company, who recently joined Transcend Therapeutics as Senior Vice President of Operations. Stephanie has worked in life sciences her whole career for various well-known firms in Greater Boston like Novartis, Agios Pharmaceuticals, Odyssey Therapeutics, and now Transcend.

Joining host David Thomann for episode #5 is Winston Yan, Co-Founder of Arbor Biotechnologies who took an idea and expanded it from him and his cofounder to about 80 over the past 5 years alone and is currently finishing up his last year of MD training at Harvard Medical School, which he had originally put on pause to found Arbor.

Joining host David Thomann for episode #4 is Emily Knight, VP of Operations, at The Engine. The Engine, built by MIT in 2017, is a venture firm that invests in early-stage companies solving the world’s biggest problems through the convergence of breakthrough science, engineering, and leadership. Their mission is to accelerate the path to market for Tough Tech companies by providing access to a unique combination of investment, infrastructure, and community.

Welcome to the third episode of Slice of Life Sciences…This week we will take our conversation from the Life Science real estate industry and focus more so on the ins and outs of managing and running a biotech company. Without further ado, Mark Tebbe, Entrepreneur in Residence for Atlas Venture, whom has had an illustrious career as a serial entrepreneur focusing on drug discovery and management in biotech/pharmaceutical industry with a broad experience involving drug development, operations, and international assignments. Mark has worked as both a consultant and full time at multiple biotechs including 3 years as co-founder and Chief Technology Officer at Quench Bio focused on severe inflammatory diseases, 3 years at Quartet Medicine as head of drug discovery focused on peripheral neuropathic pain, 3 years at Forma Therapeutics as Vice President of Medicinal and Computational chemistry building the group and delivering on a broad portfolio of cancer targets, and many more.

In today's episode, David speaks with Daniel Guadagnoli, Director at The Fallon Company. The Fallon Company is a privately held commercial real estate owner and developer of transformative, urban mixed-use environments headquartered in Boston, Massachusetts. Since 1993, The Fallon Company has developed over $6 billion in real estate, representing more than six million square feet of property. TFC has grown across the US with offices in Boston, Charlotte, Raleigh, and Nashville.

In today's episode, David speaks with Camille White, Senior Associate on BioMed Realty’s leasing team, who is a Blackstone portfolio company and leading provider of real estate solutions for the life science industry with over 14M sf worldwide in major markets like Boston, Bay Area, San Diego, Seattle, NY, and UK.